Productive Infection of Mouse Mammary Glands and Human Mammary Epithelial Cells by Zika Virus.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
15 10 2019
Historique:
received: 12 09 2019
revised: 08 10 2019
accepted: 10 10 2019
entrez: 18 10 2019
pubmed: 18 10 2019
medline: 29 9 2020
Statut: epublish

Résumé

Zika virus (ZIKV) belongs to the large category of arboviruses. Surprisingly, several human-to-human transmissions of ZIKV have been notified, either following sexual intercourse or from the mother to fetus during pregnancy. Importantly, high viral loads have been detected in the human breast milk of infected mothers, and the existence of breastfeeding as a new mode of mother-to-child transmission of ZIKV was recently hypothesized. However, the maternal origin of infectious particles in breast milk is currently unknown. Here, we show that ZIKV disseminates to the mammary glands of infected mice after both systemic and local exposure with differential kinetics. Ex vivo, we demonstrate that primary human mammary epithelial cells were sensitive and permissive to ZIKV infection in this study. Moreover, by using in vitro models, we prove that mammary luminal- and myoepithelial-phenotype cell lines are both able to produce important virus progeny after ZIKV exposure. Our data suggest that the dissemination of ZIKV to the mammary glands and subsequent infection of the mammary epithelium could be one mechanism of viral excretion in human breast milk.

Identifiants

pubmed: 31619008
pii: v11100950
doi: 10.3390/v11100950
pmc: PMC6832565
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Références

Lancet Infect Dis. 2016 Jun;16(6):653-660
pubmed: 26897108
Lancet. 2016 Mar 12;387(10023):1051
pubmed: 26944028
Cell Host Microbe. 2016 Jun 8;19(6):882-90
pubmed: 27212660
N Engl J Med. 2016 Jun 2;374(22):2195-8
pubmed: 27074370
Am J Trop Med Hyg. 2014 Nov;91(5):1035-8
pubmed: 25294619
Microbes Infect. 2018 Dec;20(11-12):646-660
pubmed: 29481868
Southeast Asian J Trop Med Public Health. 2015 May;46(3):460-4
pubmed: 26521519
Cell Host Microbe. 2016 May 11;19(5):720-30
pubmed: 27066744
Euro Surveill. 2016;21(10):30159
pubmed: 26987769
Virus Res. 2017 Jan 15;228:58-60
pubmed: 27889615
Lancet Infect Dis. 2016 Apr;16(4):405
pubmed: 26949027
Genome Announc. 2017 Apr 27;5(17):
pubmed: 28450510
Emerg Infect Dis. 2015 Jan;21(1):84-6
pubmed: 25530324
Travel Med Infect Dis. 2016 Jul-Aug;14(4):313-30
pubmed: 27425793
Euro Surveill. 2014 Jan 30;19(4):null
pubmed: 24507466
Euro Surveill. 2014 Apr 03;19(13):null
pubmed: 24721538
Paediatr Perinat Epidemiol. 2018 Jul;32(4):358-368
pubmed: 29882971
PLoS Negl Trop Dis. 2017 Apr 10;11(4):e0005528
pubmed: 28394887
Clin Infect Dis. 2018 Mar 19;66(7):1120-1121
pubmed: 29300859
Emerg Infect Dis. 2015 Feb;21(2):359-61
pubmed: 25625872
Development. 2015 Mar 15;142(6):1028-42
pubmed: 25758218
J Clin Virol. 2016 Apr;77:69-70
pubmed: 26921737
Euro Surveill. 2017 Jan 19;22(3):
pubmed: 28128730
Emerg Infect Dis. 2017 May;23(5):856-857
pubmed: 28192072
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
Biol Cell. 1992;75(3):211-6
pubmed: 1301033
Sci Rep. 2017 Sep 11;7(1):11194
pubmed: 28894118
PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007080
pubmed: 30742628
EMBO J. 2017 Jun 14;36(12):1653-1668
pubmed: 28473450
Lancet Infect Dis. 2016 Oct;16(10):1106-1107
pubmed: 27676340
Emerg Infect Dis. 2017 Jan;23(1):99-101
pubmed: 27748649
Viruses. 2019 Jun 28;11(7):null
pubmed: 31261806
Int J Infect Dis. 2017 Apr;57:70-72
pubmed: 28188933

Auteurs

Mathieu Hubert (M)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. mathieu.hubert@pasteur.fr.
Université de Paris, 75013 Paris, France. mathieu.hubert@pasteur.fr.

Aurélie Chiche (A)

Groupe à 5 ans Plasticité cellulaire et Modélisation des Maladies, Département Biologie du Développement et cellules souches, Institut Pasteur, 75015 Paris, France. aurelie.chiche@pasteur.fr.

Vincent Legros (V)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. vincent.legros@ens-lyon.fr.
Université de Paris, 75013 Paris, France. vincent.legros@ens-lyon.fr.

Patricia Jeannin (P)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. patricia.jeannin@pasteur.fr.

Thomas Montange (T)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. thomas.montange@pasteur.fr.

Antoine Gessain (A)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. antoine.gessain@pasteur.fr.

Pierre-Emmanuel Ceccaldi (PE)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. pierre-emmanuel.ceccaldi@pasteur.fr.
Université de Paris, 75013 Paris, France. pierre-emmanuel.ceccaldi@pasteur.fr.

Aurore Vidy (A)

Unité Épidémiologie et Physiopathologie des Virus Oncogènes, UMR Centre National de la Recherche Scientifique 3569, Département Virologie, Institut Pasteur, 75015 Paris, France. aurore.vidy@pasteur.fr.
Université de Paris, 75013 Paris, France. aurore.vidy@pasteur.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH